Keyphrases
Randomized Trial
100%
Targeted Therapy
100%
Progression-free Survival
100%
Advanced Renal Cancer
100%
Cochrane Systematic Review
100%
Sorafenib
75%
Sunitinib
50%
Bevacizumab
37%
Pazopanib
37%
Overall Survival
37%
Vascular Endothelial Growth Factor
37%
Temsirolimus
37%
Placebo-controlled
25%
Axitinib
25%
MTOR Inhibitor
25%
Interferon-α (IFN-α)
25%
Antiangiogenic Agents
25%
Targeted Agents
25%
Clear Cell Renal Cell Carcinoma (ccRCC)
25%
Placebo
12%
Everolimus
12%
Placebo-controlled Trial
12%
Molecular Targets
12%
Oncology
12%
Health-related Quality of Life
12%
Cancer Progression
12%
Drug Effects
12%
Standard of Care
12%
Urology
12%
Tivozanib
12%
Patient-reported Outcomes
12%
Low-risk Patients
12%
Treatment-naïve Patients
12%
MEDLINE
12%
Embase
12%
Intent-to-treat
12%
Inclusion Criteria
12%
Complete Response
12%
Cytokine Therapy
12%
Risk of Bias
12%
Number of Trials
12%
Renal Cancer
12%
First-line Regimen
12%
Epidermal Growth Factor Receptor Inhibitors
12%
Cochrane Collaboration
12%
Mammalian Target of Rapamycin Pathway
12%
Trial Closure
12%
Anti-vascular Epithelial Growth Factor
12%
Control Therapy
12%
Therapeutic Landscapes
12%
Growth Factor Inhibitors
12%
Prognostic Risk Factors
12%
Randomized Phase III Trial
12%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Progression Free Survival
100%
Sorafenib
75%
Growth Factor
50%
Placebo
50%
Sunitinib
50%
Bevacizumab
37%
Cytokine
37%
Pazopanib
37%
Overall Survival
37%
Temsirolimus
37%
Axitinib
25%
Mammalian Target of Rapamycin Inhibitor
25%
Interferon
25%
Angiogenesis Inhibitor
25%
Molecular Target
12%
Everolimus
12%
Cancer Growth
12%
Tivozanib
12%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Vascular Targeting Agent
12%
Phase III and IV Trials
12%
Mammalian Target of Rapamycin
12%